Ultima-CABER, 10 mg

Ultima-CABER 10 mg contains cabergoline, a dopamine D2-receptor agonist that primarily suppresses the secretion of prolactin. It is particularly relevant to research involving prolactin regulation, dopamine signaling, reproductive hormones, and endocrine balance. Cabergoline is an established prescription treatment for hyperprolactinemic disorders.

How it works

Cabergoline has a high affinity for dopamine D2 receptors in the pituitary gland. Activating these receptors inhibits prolactin secretion, which can influence downstream reproductive and hormonal processes.

In fitness and bodybuilding contexts, cabergoline is sometimes discussed in relation to prolactin management, particularly when elevated prolactin is associated with certain hormone-related protocols. Its primary pharmacological role, however, is controlling elevated prolactin rather than directly increasing muscle mass or strength.

Proper Use and Dosage

The listed presentation contains 10 mg of cabergoline.

The current U.S. prescribing information recommends a starting dose of 0.25 mg orally twice weekly. The dose may be increased by 0.25 mg twice weekly at intervals of at least four weeks, according to serum prolactin response. The maximum recommended dosage is 1 mg twice weekly.

For a 10 mg presentation:

• 0.25 mg = ¼ of a 1 mg equivalent
• 0.5 mg = 1 standard commercially available tablet
• 1 mg = 2 × 0.5 mg tablets
• 2 mg = 4 × 0.5 mg tablets
• 10 mg = entire 10 mg presentation

For fitness-related hormone management, cabergoline should be approached according to measured prolactin levels, rather than used simply as a routine component of an anabolic cycle.

Benefits

Ultima-CABER is particularly suited to applications involving prolactin regulation, dopamine signaling, and endocrine research.

Key benefits and areas of interest include:

• Reduces elevated prolactin levels
• Activates dopamine D2 receptors
• Supports prolactin-management research
• Relevant to reproductive-hormone regulation
• Supports endocrine-system research
• Investigated in pituitary hormone disorders
• May help restore hormonal balance when prolactin is elevated
• Relevant to research involving libido and reproductive function
• Supports dopamine-related signaling research
• Convenient 10 mg presentation

Its main value in performance-oriented hormone research comes from its ability to control prolactin, rather than providing a direct anabolic effect.

Side Effects

Possible effects include nausea, headache, dizziness, constipation, fatigue, and low blood pressure. Cabergoline also carries important warnings concerning cardiac valvular disease and fibrotic disorders, and current prescribing information recommends evaluation for valvular disease before treatment.